Optimal procedure for thermal delivery in hyperthermic/chemotherapeutic treatments in the isolated perfusion of the the limbs

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 1, 2005, Pages 35-42

  Pace, Marcello ^a,e   Millanta, L ^b   Polignano, M ^c   Gattai, R ^a   Macera Mascitelli, E ^d  

^a Section of General Surgery   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Esaote   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Chemotherapy; Hyperthermia; Limbs tumour; Perfusional technique

Indexed keywords

CANCER CHEMOTHERAPY; HUMAN; HYPERTHERMIC THERAPY; ISOLATED ORGAN; LIMB PERFUSION; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; REVIEW; TEMPERATURE MEASUREMENT; TREATMENT OUTCOME; TREATMENT PLANNING;

ANIMALS; EXTREMITIES; HUMANS; HYPERTHERMIA, INDUCED; NEOPLASMS; PERFUSION; TEMPERATURE;

EID: 18544364308     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Cavaliere R., Ciogatto B.C., Giovanelli B.C., et al.: Selective heat sensitivity of cancer cells. Cancer 20:1351-1381, 1967.
2. Bhuyan B.K.: Kinetics of cell kill by hyperthermia. Cancer Res. 39:2277-2284, 1979.
3. Hahn G.M., Shiu E.C.: Effect of pH and elevated temperature on the cytotoxicity of some chemotherapeutic agents on Chinese hamster cells in vitro. Cancer Res. 43:5789-5791, 1983.
4. Gerweck L.E.: Hyperthermia in cancer therapy: the biological basis and unresolved questions. Cancer Res. 45:3408-3414, 1985.
5. Oleson J.R., Calderwood S.K., Coughlin C.T., et al.: Biological and clinical aspects of hyperthermia in cancer therapy. Ann. J. Clin. Oncol. 11(3):365-380, 1988.
6. Issels R.D., Wilmanns (Eds.). Application of hyperthermia in the treatment of cancer. Rec. Res. Cancer Res. 107:1-271, 1988.
7. Zaffaroni N., Villa R., Daidone M.G., Vaglini M., Santinami M., Silvestrini R.: Antitumor activity of hyperthermia alone or in combination with cisplatin and melphalan in primary cultures of human malignant melanoma. Int. J. Cell Cloning 7:385-394, 1989.
8. Teicher B.A., Lazio J.S., Sartorelli A.C.: Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res. 41:73-81, 1981.
9. Dyson J.E.D., Simmons D.M., Daniel J., McLaughlin J.M., Quirke P., Bird C.C.: Kinetics and physical studies of cell death induced by chemotherapy agents or hyperthermia. Cell Tissue Kinet. 19:311-324, 1986.
10. Moulder J.E., Rockwell S.: Tumor hvpoxia its impact on cancer therapy. Cancer Met. Rev. 5:313-341, 1987.
11. Kennedy K.A.: Hypoxic cells as specific drug targets for chemotherapy. Anticancer Drug Res. 2:181-194, 1987.
12. Rockwell S.: Use of hypoxia-direct drugs in the therapy of solid tumors. Semin. Oncol. 19(11):29-40, 1992.
13. Wouters B.G., Wang L.H., Brown J.M.: Tirapazamine: A new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer. Ann. Oncol. 10(5):S29-S33, 1999.
14. Tomida A. Tsuruo T.: Drug resistance mediated by cellular stress response to the microenvironment. Anti-Cancer Drug Design 14:169-177, 1999.
15. Emami B., Song C.W.: Physiological mechanisms in hyperthermia. Int. Rad. Oncol. 10:289-295, 1984.
16. Hahn G.M.: Metabolic aspects of the role of hyperthermia in mammalian cell inactivation and their possible relevance to cancer treatment. Cancer Res. 34:3117-3123, 1974.
17. Urano M., Kuroda M., Nishimura Y.: For the clinical application of thermochemotherapy given at mild temperatures. Int. J. Hypertherm. 2:9-107, 1999.
18. Hahn G.M., Braun J., Har-Kedar I.: Thermochemotherapy: synergism between hyperthermia (42-43°C) and adriamycin (or bleomycin) in mammalian cell inactivation. Proc. Natl. Acad. Sci. USA 72:937-940, 1975.
19. Barlogie C.B., Corry P.M., Drewinko B.: In vitro thermochemotherapy of human colon cancer cells with cisdichlorodiammineplatium (II) and mitomycin. Cancer Res 40:1165-1168, 1980.
20. Dahl O., Mella O.: Hyperthermic and chemotherapeutic agents. In Field S.B., Hand J.W., eds. Introduction to the practical aspects of clinical hyperthermia 1992.
21. Koga S., Hamazoe R., Maeta M., Shimizu N., Kanamaya H.: Treatment of implanted peritoneal cancer in rats by continuous hyperthermia peritoneal perfusion in combination with anticancer drug. Cancer Res. 44(5):1840-1842, 1984.
22. Herman T.S., Teicher B.A., Jochelson M. et al.: Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. Cancer Res. 4(2):143-158, 1984.
23. Zaffaroni N., Villa R., Orlandi L., Vaglini M., Silvestrini R.: Effect of hyperthermia on the formation and removal of DNA interstrand cross-links induced by melphalan in primary cultures of human malignant melanoma. Int. J. Hypertherm. 8:341-349, 1992.
24. Orlandi L., Zaffaroni N., Bearzatto A., et al.: Effect of melphalan and hyperthermia on cell cycle progression and cyclin B1 expression in human melanoma cells. Cell Prolif. 28:617-630, 1995.
25. Orlandi L., Zaffaroni N., Bearzatto A., Silvestrini R.: Effect of melphalan and hyperthermia on p34cdc2 kinase activity in human melanoma cells. Br. J. Cancer 74:1924-1928, 1996.
26. Rietbroek R.C., van De Vaart P.J., Haveman J., et al.: Hyperthermia enhances the cytotoxic activity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J. Cancer Res. Clin. Oncol. 123:6-12, 1997.
27. Bull J.M.C.: An update on the anticancer effects of a combination of chemotherapy and hyperthermia. Cancer Res. 44:4853s-4856s, 1984.
28. Joiner M.C., Steel G.G., Stephens T.C.: Response of two mouse tumors to hyperthermia with CCNU or melphalan. Br. J. Cancer 45:19-26, 1985.
29. Murakami A., Koga S., Maeta M.: Thermochemosensitivity: Augmentation by hyperthermia of cytotoxic ity of anticancer drugs against human colorectal cancers, measured by the human tumor cologenic assay. Oncology 45:236-241, 1988.
30. Stehlin J.S.: Hyperthermic perfusion with chemotherapy for cancers of the extremities. Surg. Gynecol. Obstet. 129:305-308, 1969.
31. Schraffordt Koops H., Kroon B.B.R., Lejeune F.J.: Isolated regional perfusion in the treatment of local recurrence, satellites and in-transit metastases of extremity melanomas. Pigm. Cell 10:67-78, 1990.
32. Szmigielski S., Janiak S.: Membrane injury in cells exposed in vitro to 43°C hyperthermia. In: C Strffer (Eds.) Cancer Therapy by Hyperthermia and Radiation. Baltimore: Urban and Schwarzenberg 169-171, 1978.
33. Arcangeli G., Benassi M., Cividalli A. et al.: Radiotherapy and hyperthermia. Analysis of clinical results and identification of prognostic variables. Cancer 60:950-956, 1987.
34. Overgaard J.: The current and potential role of hyperthermia in radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 16:535-549, 1989.
35. Krementz E.T.: Regional perfusion. Current sophistication, what next? Cancer 57:416-432, 1986.
36. Kroon B.B.R., van Geel A.N., Benckhuijsen C., Wieberdink J.: Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs. Anticancer Res. 7:441-442, 1987.
37. Skene A.I., Bulman A.S., Williams T.R., Meirion, T.J., Westburg G.: Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb. Br. J. Surg. 77:765-761, 1990.
38. Neades G.T., Evans W.D., Mansel R.E.: Choice of agent and prediction of systemic toxicity in isolated hyperthermic limb perfusion. Reg. Cancer Treat. 3:252-255, 1991.
39. Klaase J.M., Kroon B.B.R., van Geel A.N., Eggermont A.M.M., Franklin H.R., Hart A.A.M.: Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma in the limbs treated with regional isolated perfusion with melphalan. Surgery 115:39-45, 1994.
40. Vrouenraets B.C., Veld G.J., Nieweg O.E., van Slooten G.W., van Dongen J.A., Kroon B.B.R.: Long-term functional morbidity after mild hyperthermic isolated limb perfusion with melphalan. Eur. J. Surg. Oncol. 25(5):503-508, 1999.
41. Ghussen F., Nagel K., Groth W., Muller J.M., Stutzer H.: A prospective randomized study of regional extremity perfusion in patients with malignant melanoma. Ann. Surg. 200:764-768, 1984.
42. Storm F.K., Morton D.L.: Value of therapeutic hyperthermic limb perfusion in advanced recurrent melanoma of the lower extremity. Am. J. Surg. 150:32-35, 1985.
43. Ghussen F., Kruger I., Groth W., Stutzer H.: The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma. Cancer 61:654-659, 1988.
44. Pace M., Galli A., Sussi S., Bellacci A.: True hyperthermia in isolated regional perfusion for the treatment of limb melanoma. Reg. Cancer Treat. 4:35, 1991.
45. Kroon B.B.R., Klaase J.M., Van Geel B.N., Eggermont A.M.M.: Application of hyperthermia in regional isolated perfusion for melanoma of the limbs. Reg. Cancer Treat. 4:223-226, 1992.
46. Vrouenraets B.C., Eggermont A.M.M., Klaase J.M., van Geel A.N., van Dongen J.A., Kroon B.B.R.: Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the lims. Eur. J. Surg. Oncol. 20(6):681-685, 1994.
47. Vrouenraets B.C.: Toxicity and morbidity of isolated limb perfusion. Amsterdam Thesis Publishers, 1997.
48. Stehlin J.S. Jr, Giovanella B.C., De Ipolyi P.D., Muenz L.R., Anderson R.F.: Results of hyperthermic perfusion for melanoma of the extremities. Surg. Gynecol. Obset. 140:339-348, 1975.
49. Kroon B.B.R., Klaase J.M., van Geel A.N., Eggermont A.M.M.: Application of hyperthermia in regional isolated perfusion for melanoma of the limbs. Reg. Cancer Treat. 4:223-226, 1992.
50. Daryanani D., de Vries E.G., Guchelaar H.J., van Weerden T.W., Hoekstra H.J.: Hyperthermic isolated regional perfusion of the limb with carboplatin. Eur. J. Surg. Oncol. 26(8):792-797, 2000.
51. Hafström L.O., Jönsson P.E.: Hyperthermic perfusion of recurrent malignant melanoma of the extremities. Acta Chir. Scand. 146:313-318, 1980.
52. Vaglini M., Ammatuna M., Nava M., et al.: Regional perfusional at high temperature in the treatment of stage IIIA-IIIAB melanoma patients. Tumori 69:585-588, 1983.
53. Cavaliere R., Calabro R., Di Filippo F., Carlini S., Giannarelli D.: Prognostic parameters in limb recurrent melanoma treated with hyperthermic antiblastic perfusion. ICRTC Ulm G7:163 Abstract, 1987.
54. Pace M., Filomena A., Galli A.: Thermal induction and temperature control in the hiperthermic antiblastic regional perfusion with extra-corporeal circulation. Consensus on Hyperthermia for the 1990s. Clinical Practice in Cancer Treatment. New York: H.I. Bicher et al. Plenum Press, 99-403, 1993.
55. Tominaga R., Kohno H., Mayumi H., et al.: Current techniques of hyperthermic isolated limb perfusion for malignant melanoma. Surg. Today 30(4):339-342, 2000.
56. Lazzerini S., Millanta L., Olmi R., Pace M.: An analysis of heat supply and temperature distribution in isolated hyperthermic perfusion of the limbs. Phys. Med. 7:135-143, 1991.
57. Pace M., Millante L., Bellacci A., Galli A., Lazzerini S.: Heat admistration temperature monitoring and control in hyperthermic antiblastic perfusion of the limbs. Reg. Cancer Treat. 4:207-212, 1993.
58. Pace M., Millanta L., Galli A., Bellacci A.: Closely controlled, highly reproducible and uniform temperature distribution in hyperthermal isolated limb perfusion. Reg. Cancer Treat. 2: 94-98, 1994.
59. Pesciullesi A., Bellacci A., Carla V., Galli A., Mini E., Pace M., Mazzei T.: Farmacocinetica del Melphalan (1-pam) durante perfusione ipertermica in pazienti con melanoma degli arti. Riunione Congiunta Monotematica sul Metabolismo degli Xenobiotici, Siena 3-4-Novembre 41. Abstract, 1995.
60. Pace M., Galli A., Bellacci A.: True hyperthermia plus double Melphalan bolus in the isolated perfusion for stage III lower limb melanoma. A pilot study. Reg. Cancer Treat. 9:1-7, 1994.
61. Pace M., Galli A., Gattai R., Macera Mascitelli E.: Perfusione isolata dell'arto. Stato attuale e prospettive nei pazienti affetti da melanoma. Arch. Arti Soc. It. Chir. 3:196-198, 2000.
62. Schraffordt Koops H.: Prevention of neural and muscolar lesions during hyperthermic regional perfusion. Surg. Gynecol. Obstet. 135:401-403, 1972.
63. Pace M.: Optimization of the vascular isolation in isolated regional perfusion of the limbs. Reg. Cancer Treat. 3:90-97, 1990.